Species Dose Scaling Explainer
Worked examples of the FDA body-surface-area formula that converts an animal dose per kilogram into a human-equivalent figure per kilogram, and of why that step misleads for peptides. The examples are fixed: there is no input for a dose and no amount for a person is ever calculated.
Educational only. This is not a dose and not a calculator for one.
This is not a dose and gives no dose.
Nothing on this page accepts an animal dose or returns an amount for a person. The examples are fixed, use a placeholder figure of 1, and show only how the conversion factor behaves.
The conversion factor, by species
The FDA converts an animal figure per kilogram into a human-equivalent figure per kilogram by multiplying by (animal Km ÷ human Km), with a human Km of 37.
| Species | Reference weight | Km | Km ÷ 37 |
|---|---|---|---|
| Mouse | 0.020 kg | 3 | 0.081 |
| Rat | 0.150 kg | 6 | 0.162 |
| Guinea pig | 0.400 kg | 8 | 0.216 |
| Rabbit | 1.8 kg | 12 | 0.324 |
| Monkey | 3 kg | 12 | 0.324 |
| Dog | 10 kg | 20 | 0.541 |
Source: FDA Guidance for Industry, July 2005, Tables 1 and 3. The guidance rounds the rat factor to 0.16 in Table 1 and prints 0.162 in Table 3.
Three worked examples of why the step misleads
- The answer depends on the species you picked. Take an animal figure of 1 per kg. Converted from a mouse it becomes 0.081; from a rat 0.162; from a dog 0.541. The same number gives a 6.7-fold spread across species before any biology is considered.
- The factor is not constant even within one species. The guidance notes that the Km of a rat runs from 5.2 at 100 g to 7.0 at 250 g, and that the standard value of 6 applies only at the 150 g reference weight. The conversion is built for weights inside a stated range.
- The number answers a different question from an effect dose. The guidance derives a maximum recommended starting dose for a first-in-human trial in healthy volunteers, from the highest dose with no observed adverse effect in animals, then divides by a safety factor (default 10). A dose that produced an effect in a rodent injury or metabolism model is not that input, and the guidance lists differences in receptor density or affinity and in absorption, distribution, metabolism and excretion among the reasons the margin is needed.
The answer can be misleading for peptides.
The conversion is a safety-margin heuristic for the first human dose of a drug entering a Phase I trial, not a pharmacological predictor. For peptides, absorption, half-life, receptor affinity and protein binding can all differ between species in ways body surface area does not capture. See our allometric-scaling-failures page for the longer treatment.
The FDA Km formula
The FDA’s 2005 guidance Estimating the Maximum Safe Starting Dose in Initial Clinical Trials for Therapeutics in Adult Healthy Volunteers normalises interspecies doses by body surface area rather than mass. Each species has a “Km factor” (roughly weight-in-kg ÷ surface-area-in-m²). The conversion is:
HED (mg/kg) = animal (mg/kg) × (animal Km / human Km)
For a mouse (Km 3) and human (Km 37) the factor is 3/37, about 0.081: an animal figure of 1 per kilogram becomes about 0.081 per kilogram. The guidance treats that result as an input to a first-in-human safety margin, which is why this page stops there and does not turn it into an amount for a person.
Why the answer can be misleading for peptides
The Km formula was derived from small-molecule toxicology data — drugs that distribute freely into aqueous compartments and clear through renal or hepatic pathways whose scaling roughly tracks body surface area. Peptides break this in several ways:
- Absorption from subcutaneous / intramuscular sites depends on lipophilicity, formulation, and injection-site perfusion — not on body surface area.
- Plasma half-life is dominated by proteolytic enzymes and receptor-mediated clearance, both of which vary non-allometrically between species.
- Slow-absorption formulations, such as fatty-acid-modified peptides that bind albumin, can give a plasma profile that is not a simple decay curve.
- Receptor affinity at the target can differ between the animal orthologue and the human receptor — the same molar concentration produces different biological effects.
A more thorough treatment lives on the allometric-scaling-failures page, with worked examples from the published peptide literature.
What this tool is not
- Not a starting-dose recommendation. Even in the FDA framework the HED is divided by a default safety factor of 10, which the guidance says can be raised or lowered on the evidence — and that is specifically for a Phase I first-in-human trial with monitoring, not for use outside one.
- Not a substitute for the actual pharmacokinetic study. Where a peptide has been measured in people, as in the Enebo 2021 phase 1b trial of cagrilintide given with semaglutide (PMID 33894838), the human data is a better guide than extrapolation from animals.
- Not a signal to trust any body of preclinical-only evidence. Rodent dose-response curves are a starting point for research, not a substitute for human studies.